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ABSTRACT
The aim of this study was to investigate the prognostic value of 18F-fluoro-
deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/
CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed 
recurrence after stem cell transplantation (SCT). All patients had been heavily pre-
treated. Time to progression (TTP) and overall survival (OS) were correlated to a 
number of different PET-derived as well as clinical parameters. Impact on patient 
management was assessed.
Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and 
OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS 
(p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved 
to have the strongest association with disease progression. Intensity of glucose 
uptake and presence of extramedullary disease were associated with shorter TTP 
(p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned 
out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). 
PET resulted in a change of management in 30% of patients.
Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients 
also in the setting of post-SCT relapse. PET/CT has a significant impact on patient 
management.
INTRODUCTION
Multiple myeloma (MM) accounts for 
approximately 1% of all cancers and around 10% of 
hematological malignancies [1, 2]. Although overall 
survival has improved over the last decade, MM essentially 
remains incurable. Besides conventional chemotherapeutic 
agents, an increasing number of ´novel` drugs have 
been evaluated, including the proteasome inhibitor 
bortezomib, the anti-angiogenic agent thalidomide and 
its immunomodulatory derivatives lenalidomide and 
pomalidomide [3]. A significant survival benefit has been 
reported for autologous stem cell transplantation (SCT) 
[4]. Allogeneic stem cell transplantation exploits immune 
surveillance of myeloma plasma cells by grafting stem 
cells derived from a HLA-identical sibling or unrelated 
donor; however, its application is limited by severe 
complications as well as graft-versus-host disease that 
may arise after conditioning and SCT.
Several studies have demonstrated the utility of 
molecular imaging using positron emission tomography 
(PET) and the radiolabeled glucose analog 18F-2`-deoxy-
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2`-fluorodeoxyglucose (18F-FDG) for diagnosis, staging 
and estimation of prognosis, leading to implementation 
into the revised Salmon/Durie staging system (Salmon/
Durie PLUS) [5-11]. However, most studies assessing 
the prognostic implication of PET have focused on early 
therapeutic settings prior to SCT [12-14]. In a study 
enrolling 77 patients with previous autologous SCT, Nanni 
and co-workers found a negative PET scan to be predictive 
for a longer disease-free survival. On the other hand, 
patients with persisting myeloma activity, as indicated by 
PET, had a significantly shorter time to relapse [15]. The 
value of molecular imaging in the setting of relapse after 
SCT has not been examined yet. Recently, the International 
Myeloma Working Group emphasized the need for further 
studies before PET could be recommended as a standard 
tool in both diagnosis and follow-up of MM patients [16].
The aim of this study was to investigate the 
prognostic role of 18F-FDG-PET in patients with multiple 
myeloma relapse after autologous and/or allogeneic stem 
cell transplantation. Impact of 18F-FDG-PET on patient 
management was also assessed.
RESULTS
Imaging characteristics 
Out of 37 patients with serologically proven relapse 
from multiple myeloma, 28 (76%) had a positive PET 
scan. Fourteen out of those (50%) presented with disease 
confined to the bone marrow compartment (intramedullary 
lesions), 11 patients (39%) suffered from both intra- and 
extramedullary disease and the remaining 3 patients (11%) 
had exclusively extramedullary MM manifestations, 
resulting in 50% (14/28) of PET-positive patients with 
extramedullary manifestations. Regarding EMD, lymph 
node involvement was most commonly seen (11/14, 
79%), followed by manifestations of soft tissue (6/14, 
43%), liver (4/14, 29%), spleen (2/14, 14%) and lungs 
(2/14, 14%). Regarding intramedullary MM, 16/28 PET-
positive patients (57%) also showed involvement of the 
appendicular skeleton, with 7/16 (44%) also presenting 
with EMD. In 9 patients (24%) with serological relapse, 
no metabolically active MM lesions could be detected 
(Figure 1). PET negativity turned out to be a positive 
prognostic factor: In the group of patients with a negative 
18F-FDG scan, median TTP was not reached (vs. 6.8±2.0 
m in PET-positive patients; p=0.01) and only one of those 
subjects deceased not MM-related (endocarditis) during 
follow-up (OS not reached; vs. 21.4±10.4 m for PET-
Figure 2: Prognostic impact of PET-positivity on time to progression and overall survival. Kaplan-Meier analysis of patient 
outcome according to presence of PET-positive lesions.
Figure 1:Lesion detection by PET/CT in posttransplant 
myeloma patients. Out of 37 patients undergoing 18F-FDG-
PET/CT, 28 (76%) had a positive scan. 14 out of those 28 
(50%) presented with disease confined to the intramedullary 
compartment (IMD = intramedullary disease), 11/28 patients 
(39%) suffered from both intra- and extramedullary disease 
(IMD + EMD) and the remaining 3/28 patients (11%) had 
exclusively extramedullary MM manifestations. 16 patients 
(57%) also showed involvement of the appendicular skeleton, 
with 7/16 (44%) also presenting with EMD. In 9/37 patients 
(24%) with serological relapse, no metabolically active MM 
lesions could be detected. 
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positive patients; p=0.069; Figure 2).
Number and location of intramedullary lesions
Of the 25/37 (68%) patients who presented with 
intramedullary focal PET-positive lesions, 9/25 subjects 
(36%) had 1-10 PET-positive lesions, the remainder 
(16/25; 64%) showed >10 focal lesions. The number of 
lesions proved to be a significant prognostic factor. In 
patients with 1-10 lesions, a significantly longer TTP as 
well as OS was observed, as compared to those with more 
than 10 intramedullary lesions. Median TTP was 10.0±6.8 
m and median survival was not reached in patients with ≤ 
10 lesions, whereas TTP was 4.1±2.2 m and OS 7.0±3.3 
m (TTP p=0.003; OS p=0.023) in patients with >10 
intramedullary lesions (Figure 3A). 
In the subgroup of patients with involvement 
of the appendicular skeleton, 6/16 patients (37%) had 
1-10 lesions and 10/16 (63%) had >10 lesions. Here, a 
high number of lesions was associated with significantly 
shorter TTP (2.2±0.8 months; p<0.001) and OS (4.7±0.6 
months; p<0.001). In the cohort with less than 10 lesions, 
overall median TTP was significantly longer 10.0±2.2 m 
(p<0.001) and OS was not reached (p<0.001) (Figure 3B). 
Number and location of extramedullary lesions
In 14/37 (38%) patients with extramedullary 
disease, TTP and OS was shorter than in the patients with 
no EMD (median TTP 3.2±3.4 m vs. 29.3±0.0 m, p=0.049; 
median OS 8.8±1.5 m vs. not reached, p=0.172; Figure 
4A). However, sub-analysis of disease allocation revealed 
that presence of myeloma lesions in soft tissue structures 
(6/37, 16%) was associated with significantly shorter 
median TTP and median OS (Figure 4B). Subjects with 
soft tissue involvement turned out to have a median TTP of 
1.4±0.5 months (vs. 10.2±5.2 m in all patients without soft 
tissue involvement; p=0.008) and a median OS of 4.7±3.3 
months (vs. OS not reached; p=0.003). In comparison 
to patients with EMD and involvement of other organs, 
absence of soft tissue lesions was associated with an 
improved median TTP of 10.2±4.0 months (p=0.021) 
and median OS was not reached (p=0.013). Figure 5 
shows an example of soft tissue involvement and limited 
survival of 8 months despite multidrug therapy including 
novel compounds. Interestingly, soft tissue involvement 
was associated with extensive intramedullary disease 
(>10 intramedullary lesions) in 5/6 (83%) patients. The 
remaining patient without intramedullary MM suffered 
Figure 3: Prognostic impact of number and location of intramedullary lesions on time to progression and overall 
survival. A) Kaplan-Meier analysis of outcome according to the number of PET-positive intramedullary lesions. B) Kaplan-Meier analysis 
of outcome according to the number of PET-positive focal lesions (FL) in the appendicular skeleton.
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from co-existing LN involvement, which occurred in the 
majority of EMD cases (11/14, 79%). On its own, presence 
of nodal involvement was associated with a slightly longer 
median TTP (6.6±3.2 m) and median OS 8.8±0.0 m as 
compared to EMD without LN involvement (median TTP 
2.2±0.76 m, p=0.097; median OS 7.0±1.9 m, p=0.379). 
Activity of lesions
In the 28 patients with a positive PET scan, hottest 
lesion activity, as assessed by SUVmax in intra- and 
extramedullary lesions, was correlated to TTP or OS. 
Using ROC analysis, cut-off values designating inferior 
outcome were derived. A value of SUVmax>18.57 was 
predictive for shorter TTP (median 7.0±3.2 m vs. not 
reached; p=0.037). OS could not significantly be related 
to lesion activity. However, there was a trend to inferior 
survival when lesion activity was >10.36 (p=0.104).
Predictive value of cytogenetics
In the 23 patients screened for cytogenetic 
abnormalities, high risk signatures occurred in 9/23 
(39%). Out of these, 7/9 (78%) had a positive PET scan, 
6/7 (86%) presented with >10 and 1/7 (14%) with ≤10 
focal lesions. The remaining patients (2/9, 22%) were PET 
negative as compared to 7/14 (50%) subjects with standard 
risk profiles. EMD could be detected in 4/9 (44%) high-
risk patients (vs. 3/14 (21%) with standard risk). Overall, 
unfavorable cytogenetics were also associated with 
shorter median TTP (6.8±6.8 m, p=0.364) and median 
OS (9.0±3.03 m, p=0.047). Furthermore, in 6/9 subjects 
(67%) with high-risk profiles, disease progression was 
observed (median TTP 6.8±6.8 m; median OS 9.0±3.0 
m) whereas only 4/14 (29%) patients with standard risk 
profiles deceased during follow-up (median TTP 29.3±0.0 
m, p=0.108; median OS not reached, p=0.044).
Predictive value of laboratory characteristics 
Regarding biochemical work-up, 10/37 patients 
(27%) presented with elevated LDH levels (>250 U/l). 
Elevated LDH was associated with a positive PET scan 
(9/10, 90%). Interestingly, 8/9 PET-positive patients (89%) 
presented with >10 lesions and also had appendicular 
intramedullary lesions. EMD was present in 60% (6/10). 
7/10 patients (70%) with elevated LDH at the time point 
Figure 4: Prognostic impact of extramedullary disease. A) Kaplan-Meier analysis of outcome according to presence of 
extramedullary disease itself. B) Sub-analysis regarding outcome according to presence of soft tissue involvement. 
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of PET scanning died (median TTP 2.2±0.84 m, p=0.001; 
OS 4.7±0.5 m, p<0.0001; Figure 6A). 
β2-microglobulin levels were >3.5-5.4 mg/l in 
5/30 (16.7%) and >5.5 mg/l in 6/30 (20%) patients. 
The remaining 19 patients (63%) with available data 
presented with β2M levels <3.5 mg/l. Elevation of β2M 
proved to be a negative prognostic factor: In 4/5 (80%) 
patients with intermediate β2M levels (3.5-5.4 mg/l), the 
PET scan returned positive findings (3/5 (60%) patients 
presenting with >10 intramedullary lesions and in 2 
patients (40%) with EMD). 4/5 patients (80%) progressed 
and 3/5 (60%) died during follow-up with a median TTP 
of 4.0±1.6 m (p=0.01) and OS of 4.7±0.8 m (p<0.001), 
respectively. In the high-risk group with β2M levels >5.5 
mg/l, 5/6 patients (83%) were PET positive and had >10 
intramedullary lesions with 4/6 (66.7%) showing EMD. 
All patients deceased with a median TTP of 1.4±0.7 m 
(p=0.014) and OS of 3.1±1.7 m (p<0.0001) (Figure 6B). 
Free light chains were elevated in every patient. 
12/37 (32%) patients had FLC levels >100 mg/l. Severe 
FLC elevation was strongly associated with a positive PET 
scan (12/12), with more than 10 focal skeletal lesions in 
10/12 (83%) cases. The remaining 2/12 patients (17%) had 
1-10 focal lesions. Regarding the appendicular skeleton, 
>10 lesions were present in 8/12 (67%) cases, 1-10 lesions 
in 2/12 (17%) cases. EMD was present in 8/12 (67%), as 
compared to 6/25 (24%) cases with FLC<100. 
High-risk cytogenetics were found in 6/12 (50%) 
patients. Presence of FLC levels >100 mg/l was associated 
with significantly shorter TTP (median 4.7±3.8 m, 
p=0.022) and OS (median 7.0±3.3 m, p=0.049; Figure 
6C).
Figure 5: Negative prognostic value of extramedullary soft tissue lesions. Display of three patients without (A) and with (B; 
C) extramedullary myeloma manifestations. Whereas patient A had exclusively intramedullary lesions, patients B and C presented with 
intramedullary and extramedullary disease. Patient B had mainly iliac lymph node involvement (arrow), patient C suffered from muscle 
manifestations (arrow). All patients received chemotherapy with novel agents after 18F-FDG-PET/CT; follow-up was 8 months in all. 
Whereas patients A and B have not progressed yet, patient C died 8 months after the PET scan. EMD = extramedullary disease, LN = lymph 
node, TTP = time to progression
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Impact of 18F-FDG-PET/CT scans on patient 
management
In 11 of the 37 cases (30%), PET/CT directly 
influenced treatment decisions: in 2 patients, PET/CT 
indicated disease activity which had not been revealed at 
routine follow-up (diffuse, non-secretory bone marrow 
relapse and solitary extramedullary manifestation, 
respectively). In the remaining 9 patients with 
intramedullary myeloma relapse, previously unknown 
extramedullary disease was detected de novo. In the 
patient with non-secretory relapse systemic treatment 
for what previously had been deemed fever of unknown 
origin was initiated. Treatment intensification (multi-agent 
chemotherapy and stem cell transplant, respectively) based 
upon the PET findings was performed in the other 10 
patients. 
Figure 6: Prognostic impact of biochemical serum parameters: A) lactate dehydrogenase (LDH), B) β2-microglobulin, 
and C) free light chains. Kaplan-Meier analysis of outcome according to presence of elevated levels of LDH (>250 U/l) (A), β2-
microglobulin (>3.5 mg/l) (B) and free light chains (kappa or lambda, respectively; >100 mg/l) (C).
Oncotarget7387www.impactjournals.com/oncotarget
DISCUSSION 
This is the first study to analyze prognostic utility 
as well as clinical impact of FDG-PET/CT in relapsed 
multiple myeloma patients after allogeneic and/or 
autologous SCT. In this unique cohort of 37 subjects, PET 
negativity was significantly correlated with longer TTP 
and OS whereas presence of FDG-avid disease, especially 
a high number of focal lesions (FL) with involvement of 
the appendicular skeleton and/or extramedullary disease 
with soft tissue lesions was predictive of unfavorable 
outcome. 
The role of the number of PET-avid FL as an 
adverse prognostic factor has already been introduced in 
previously untreated MM patients [13, 14]. Interestingly, 
in our patient collective -besides the overall involvement 
of the skeleton- the number of detected lesions (>10) in 
the appendicular skeleton was particularly correlated with 
shorter TTP and OS. The impact of the distribution of bone 
lesions has already been reported for prostate cancer [17-
19]. One study investigating 86 prostate cancer patients 
with bone metastases reported on better prognosis of axial 
as compared to appendicular metastases [19]. The authors 
speculated that appendicular involvement portended a 
worse prognosis due to higher tumor volume. In MM, 
extension of malignant plasma cells to the extremities 
might also identify higher tumor burden as well as more 
aggressive biology.
Presence of EMD has also been established as an 
independent unfavorable prognostic factor [6, 13, 14]. In 
our cohort, we could confirm that also in patients after 
SCT the presence of EMD is associated with shortened 
TTP (and OS). Interestingly, there was a much stronger 
correlation with both TTP and OS when extramedullary 
lesions were present in soft tissue structures. As soft tissue 
lesions occurred mostly in patients with extensive intra- 
(and extra-) medullary disease, this might be explained by 
the presence of very advanced disease. 
In parallel to studies enrolling patients with 
newly diagnosed MM directly prior to or after up-front 
autologous SCT [12], intensity of FDG uptake was 
negatively correlated with TTP. However, the threshold 
of SUVmax observed in our series was substantially higher 
as previously reported (SUVmax>18.57 vs. SUVmax>4.2). 
This is partly in line with a recent report that did not find 
any statistically significant difference in SUVmax<4.2 after 
up-front SCT in PET-positive patients who subsequently 
relapsed and in PET-positive patients who presented with 
stable disease [15]. This observation might be explained 
by the late-stage patient collective presenting with more 
aggressive and thereby highly metabolically active 
disease. The value of SUVmax might reside in treatment 
assessment but this requires further elucidation.
We additionally investigated the association between 
established laboratory serum parameters and 18FDG-PET. 
Elevated LDH (>250 U/l), β2M (>3.5 mg/dl) as well as 
severely elevated FLC levels (>100 mg/l) correlated with 
a positive PET scan, the number of focal lesions, EMD 
as well as TTP and OS. Therefore, 18FDG-PET/CT might 
prove especially useful for the treating physician when 
local therapies -either alone or as an adjunct to systemic 
treatments- are considered in patients with increasing 
serum markers: it is able to demonstrate individual entities 
of disease involvement and thereby stratify prognostic 
subgroups starting from patients with a negative scan PET 
scan to subjects with widespread extramedullary disease. 
Additionally to its diagnostic value, PET/CT also 
directly influenced treatment decisions in approximately 
one third of cases (11/37) leading to treatment initiation 
(1/11) or intensification (multi-agent chemotherapy and 
stem cell transplant, respectively (10/11)). By depicting 
more widespread disease, PET/CT might directly impact 
treatment approaches in patients who are (still) eligible 
for therapy and may even benefit from more aggressive 
therapies. 
This study has a number of limitations. First, 
its retrospective design and low patient numbers 
limit statistical power. Second, no comparison with 
conventional imaging modalities such as magnetic 
resonance imaging (MRI) or CT was performed. This was 
out of the scope of this study which concentrated on the 
predictive value of PET. Additionally, MR and CT scans 
were performed on different scanners using different 
protocols in some cases, thereby hampering direct 
comparison. Since not all positive MM lesions, especially 
extramedullary manifestations, were histologically proven, 
there might be a false positive rate, e.g. for lymph node 
involvement. It is not clear if – and to which extent – 
individual treatment decisions based of PET/CT imaging 
might have influenced patients’ overall prognosis. It could 
be speculated that switching a given patient to a more 
“intensive treatment pathway”, based on PET/CT findings, 
may ultimately result in more favourable outcomes. 
However, data indicating more intensive systemic 
therapies being superior to less intensive ones are not 
unequivocal [20, 21] and are especially not convincing in 
widespread extramedullary multiple myeloma [22]. In all, 
treatment-induced bias due to heterogeneous treatments at 
relapse cannot be excluded in this series and may account 
for some of the prognostic differences that were found. 
It is only by a prospective trial that one will be able to 
eliminate efficacy-related influence. 
In summary, our data underline the prognostic value 
of 18F-FDG-PET/CT in multiple myeloma in relapsed 
patients after SCT. PET seems to be reliable in predicting 
outcome by depicting the extent of active disease and 
distinguishing different subgroups of patients with distinct 
myeloma biology. Additionally, implementation of PET 
into the diagnostic algorithm has an impact on patient 
management in about 30% of cases and might raise the 
opportunity for treatment individualization in the future.
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Table 1: Patients` characteristics 







1 m 60 IgA λ high risk 7.6 CTx, RTx yes yes
2 m 59 IgA λ n/a 7.9 CTx, RTx yes yes
3 f 71 IgG κ other 9.8 CTx, RTx yes none
4 m 51 light chain κ other 3.1 CTx, RTx yes none
5 f 63 light chain κ other 1.5 CTx, RTx yes none
6 m 52 IgG κ high risk 4.8 CTx, RTx yes yes
7 m 54 IgG κ other 6.8 CTx, RTx none yes
8 m 50 IgA κ other 1.5 CTx, RTx yes none
9 m 75 IgG λ n/a 3.1 CTx yes none
10 f 51 IgA κ other 1.4 CTx, RTx yes none
11 m 72 IgG κ n/a 3.1 CTx yes none
12 m 39 IgG κ n/a 4.7 CTx, RTx yes none
13 m 44 IgG κ other 11.1 CTx, RTx yes none
14 m 49 IgA κ high risk 6.6 CTx, RTx yes yes
15 m 54 IgA λ high risk 2.1 CTx yes none
16 m 67 light chain κ n/a 6.5 CTx yes yes
17 f 59 IgG κ high risk 4.8 CTx, RTx yes yes
18 m 50 light chain κ high risk 1.5 CTx, RTx yes none
19 m 51 IgG κ other 2.9 CTx, RTx yes none
20 m 64 IgG λ n/a 7.5 CTx yes yes
21 m 55 IgA λ other 2.5 CTx, RTx yes none
22 m 67 IgG λ n/a 3.6 CTx, RTx yes yes
23 m 57 IgG λ other 9.4 CTx, RTx yes yes
24 m 58 IgG κ other 0.6 CTx, RTx yes none
25 f 64 IgG λ other 4.0 CTx, RTx yes yes
26 m 49 IgA λ high risk 4.7 CTx yes yes
27 m 63 IgG λ n/a 0.4 CTx, RTx yes none
28 m 69 IgG k other 3.2 CTx, RTx yes none
29 m 63 IgA λ high risk 1.0 CTx yes none
30 f 72 Ig G λ n/a 6.8 CTx, RTx yes none
31 m 72 IgG k n/a 14.2 CTx, RTx yes none
32 m 53 Ig A λ n/a 6.0 CTx, RTx yes yes
33 m 69 IgG λ other 3.6 CTx yes none
34 f 65 light chain κ n/a 5.2 CTx, RTx yes none
35 m 52 IgG k n/a 2.8 CTx, RTx yes yes
36 f 75 IgG λ high risk 0.6 CTx yes none
37 m 54 IgG λ n/a 7.8 CTx, RTx none yes
High-risk cytogenetics included the presence of del(17p), t(4;14), t(14;16), t(14;20) and chromosome 1 abnormalities, 
whereas all other karyotypes were classified as standard risk. Disease duration is given in years. CTx = chemotherapy 
including novel agents, RTx = radiotherapy. Auto-Tx = autologous stem cell transplant, allo-Tx = allogeneic stem cell 
transplant. N/A = information not available.
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MATERIALS AND METHODS
Due to the retrospective nature of this study, our 
institutional review board waived the requirement for 
informed consent. Still, all patients gave written informed 
consent to receive 18F-FDG-PET/CT imaging for the 
purpose of restaging and assessment of disease activity.
Patients
Between September 2010 and August 2013, 37 
patients (29 males, 8 females, age 39-75 y, mean 60±9 
y) with a history of multiple myeloma were enrolled. 
All patients suffered from long-standing disease (mean 
duration 4.7±3.2 y) and had been pre-treated with a 
number of various chemotherapies, including novel 
agents such as bortezomib, lenalidomide and others. 
Radiation therapy had been administered to 28/37 patients 
(76%). 35/37 subjects (95%) had undergone autologous 
SCT, 15/37 (41%) primary (2/37) or additional (13/37) 
allogeneic SCT. Detailed patients´ characteristics are 
given in Table 1. 
At the time point of PET/CT imaging, recurrent 
disease was proven or highly suspected due to increased 
serological disease activity. After PET/CT, patients were 
monitored regardless of initiated therapies. 16/37 (43%) 
patients received further systemic therapy, 9/37 (24%) 
underwent allogeneic SCT, 2/37 (5%) underwent radiation 
therapy and 1/37 (3%) had combined radiochemotherapy. 
For the subcohort of survivors, median follow-up was 
13 months (range 3-29 months) and for patients who 
deceased during follow-up, median time-to-death was 5 
months (range 1-21 months).
Time to progression (TTP) and overall survival 
(OS) were correlated to a number of different PET-
derived (SUVmean; SUVmax) as well as clinical parameters 
(lactate dehydrogenase [LDH], β2 microglobulin [β2M], 




18F-FDG was synthesized in house with a 16 MeV 
Cyclotron (GE PETtrace 6; GE Healthcare, Milwaukee, 
USA) using GE FASTlab methodology according to the 
manufacturer’s instructions. Before use, radiochemicals 
were analyzed by HPLC for radiochemical identity and 
purity. 
PET/CT
PET/CT was performed on a PET/CT scanner 
(Siemens Biograph mCT 64, Siemens, Knoxville, USA) 
consisting of a lutetium oxyorthosilicate full-ring PET and 
a 64-slice spiral CT. 18F-FDG (316 ± 30 MBq) was injected 
intravenously. After a period of 60 min, transmission data 
were acquired using contrast-enhanced spiral CT (dose 
modulation with a quality reference of 210 mAs, 120 kV, 
a 512 × 512 matrix, 5 mm slice thickness, increment of 
30 mm/s, rotation time of 0.5 s, and pitch index of 0.8) 
including the base of the skull to the proximal thighs. 
Consecutively, PET emission data were acquired in 
3D-mode with a 200 × 200 matrix with 2 min emission 
time per bed position. After decay and scatter correction, 
PET data were reconstructed iteratively with attenuation 
correction using a dedicated software (HD. PET, Siemens 
Esoft, Erlangen, Germany). Standard criteria to define 
lesions as PET/CT positive were applied according to 
Zamagni et al. [12]. Briefly, presence of areas of focally 
increased tracer uptake within bones (e.g. more intense 
compared to normal bone marrow (BM) uptake) excluding 
articular processes, with or without corresponding 
lesion identified by CT were rated positive for multiple 
myeloma; alternatively, a maximum standardized uptake 
value of SUVmax ≥ 2.5 within osteolytic lesions exceeding 
1 cm in size or SUVmax > 1.5 within osteolytic lesions 
ranging between 0.5 and 1 cm in size were rated positive. 
Up to 10 lesions were recorded. If subjects presented 
with more than 10 lesions (FL), they were categorized 
into the subgroup >10 FL. Lesions in the appendicular 
skeleton were divided from those in the axial portions. 
Diffuse BM involvement was considered if the tracer 
uptake was diffusely increased with a SUVmax equal to 
or greater than the uptake in the spleen. SUVmax of the 
hottest intramedullary lesion was measured. Presence 
of extramedullary disease (EMD), defined as FDG-avid 
lesions that, according to corresponding CT sections, 
was not contiguous to bone or arose in soft tissue, were 
described by lesion location and the number of lesions 
was recorded. Paramedullary disease arising from bone 
was considered as a myeloma lesion but not as EMD. In 
parallel to medullary disease, SUVmax and location of the 
hottest extramedullary lesion were recorded.
Laboratory investigations
At the time point of 18FDG-PET/CT scanning, 
a variety of laboratory parameters were evaluated for 
their prognostic impact. Free immunoglobulin light 
chains ([FLC]; all patients) were recorded. Levels of 
β2-microglobulin ([β2M]; available in 30 patients) 
and lactate dehydrogenase ([LDH]; all patients) as 
known prognosticators for an adverse prognosis were 
documented as well. Additionally, interphase molecular 
cytogenetics based on fluorescence in situ hybridization 
(FISH) were available in 23/37 patients (62%). Presence 
of del(17p), t(4;14), t(14;16), t(14;20) and chromosome 1 
abnormalities were considered as high-risk, whereas all 
other karyotypes were classified as standard risk.
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Statistical analysis
Statistical analyses were performed using PASW 
Statistics software (version 22.0; SPSS, Inc. Chicago, 
IL). Quantitative values were expressed as mean ± 
standard deviation or median and range as appropriate. 
Comparisons of related metric measurements were 
performed using Wilcoxon-signed rank test. The Chi 
square- or Fisher exact test was conducted for comparison 
of frequency data between independent subgroups. 
Survival probabilities were calculated according to the 
Kaplan-Meier method and the log-rank test was used 
for statistical comparison of survival curves between 
independent subgroups. All statistical tests were performed 
two-sided and a p-value < 0.05 was considered to indicate 
statistical significance. No correction of p-values was 
applied to adjust for multiple tests. 
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